Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Chimeric antigen receptor T cell (CART) therapy is currently one of the most promising treatment approaches in cancer immunotherapy. However, the immunosuppressive nature of the tumor microenvironment, in particular increased reactive oxygen species (ROS) levels, provides considerable limitations. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Hyeon Joo, Liu, Yibin, Wang, Lei, Schubert, Maria-Luisa, Hoffmann, Jean-Marc, Wang, Sanmei, Neuber, Brigitte, Hückelhoven-Krauss, Angela, Gern, Ulrike, Schmitt, Anita, Müller-Tidow, Carsten, Dreger, Peter, Mokhir, Andriy, Schmitt, Michael, Sellner, Leopold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566309/
https://www.ncbi.nlm.nih.gov/pubmed/31109083
http://dx.doi.org/10.3390/ijms20102469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566309/
https://www.ncbi.nlm.nih.gov/pubmed/31109083
http://dx.doi.org/10.3390/ijms20102469

Ejemplares similares